Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-23

Clinical Trial Update: Saizen® E-Device User Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Saizen's E-Device for growth disorders has been completed, with results posted in July 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Saizen (somatropin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Growth Disorders | Phase 3 | Status: COMPLETED | Results posted: 2018-07-23